<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="3979439b-eb29-4d90-9c6e-32e6b2a02e7a"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use KETALAR<sup>®</sup> safely and effectively. See full prescribing information for KETALAR.</content>
      <br/>
      <br/>
      <content styleCode="bold">KETALAR (ketamine hydrochloride) injection, for intravenous or intramuscular use, CIII </content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 1970</content>
   </title>
   <effectiveTime value="20220330"/>
   <setId root="14e8f864-8b8a-4e7e-8439-e510d3107063"/>
   <versionNumber value="23"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="119185057" root="1.3.6.1.4.1.519.1"/>
            <name>Endo USA, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="c02d8c49-fa65-4ce9-b416-f796991c426d"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20240912"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="42023-113" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Ketalar</name>
                        <formCode code="C42946" displayName="INJECTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>ketamine hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="10"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="O18YUO0I83" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>KETAMINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="690G0D6V8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>KETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PH41D05744" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZETHONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="20"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" displayName="VIAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="42023-113-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20071001"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA016812" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20071001"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48676" displayName="CIII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C28161" displayName="INTRAMUSCULAR" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" displayName="INTRAVENOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="42023-114" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Ketalar</name>
                        <formCode code="C42946" displayName="INJECTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>ketamine hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="50"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="O18YUO0I83" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>KETAMINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="690G0D6V8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>KETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PH41D05744" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZETHONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="10"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" displayName="VIAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="42023-114-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20071001"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA016812" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20071001"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48676" displayName="CIII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C28161" displayName="INTRAMUSCULAR" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" displayName="INTRAVENOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="42023-115" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Ketalar</name>
                        <formCode code="C42946" displayName="INJECTION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>ketamine hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="100"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="O18YUO0I83" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>KETAMINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="690G0D6V8H" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>KETAMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PH41D05744" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZETHONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="5"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43226" displayName="VIAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="10"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="42023-115-10" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20071001"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA016812" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20071001"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48676" displayName="CIII" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C28161" displayName="INTRAMUSCULAR" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38276" displayName="INTRAVENOUS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_87830e83-2c8e-4576-9b1a-513431ac82a4">
               <id root="70019eb7-a500-4e1d-8747-245cd1ae95e4"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph> KETALAR (ketamine hydrochloride) injection is indicated:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation.</item>
                     <item>for the induction of anesthesia prior to the administration of other general anesthetic agents.</item>
                     <item>as a supplement to other anesthetic agents.</item>
                  </list>
               </text>
               <effectiveTime value="20220330"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>KETALAR is a general anesthetic indicated:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>as the sole anesthetic agent for diagnostic and surgical procedures that do not require skeletal muscle relaxation (<linkHtml href="#LINK_1a6f4178-94d7-43cf-a243-875c3966f480">1</linkHtml>)</item>
                           <item>for the induction of anesthesia prior to the administration of other general anesthetic agents (<linkHtml href="#LINK_1a6f4178-94d7-43cf-a243-875c3966f480">1</linkHtml>)</item>
                           <item>as a supplement to other anesthetic agents (<linkHtml href="#LINK_1a6f4178-94d7-43cf-a243-875c3966f480">1</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_8e55e584-0e01-429c-8fa0-67521f68a2f1">
               <id root="36ee1b7a-2683-4871-9144-0d72a2c4b8a0"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20220330"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>See Full Prescribing Information for important dosage and administration instructions. (<linkHtml href="#LINK_38e973d4-e1e3-4cf2-b682-251097990ee2">2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Induction of anesthesia:</content>
                              <paragraph>--<content styleCode="italics">Intravenous route</content>:  Initially, 1 to 4.5 mg/kg administered slowly (over a period of 60 seconds). Alternatively, administer a dose of 1 to 2 mg/kg at a rate of 0.5 mg/kg/min. (<linkHtml href="#LINK_c2d0a5b6-befc-4a12-bb22-f0dd304ae332">2.2</linkHtml>)<br/> --<content styleCode="italics">Intramuscular route</content>:  Initially, 6.5 to 13 mg/kg. (<linkHtml href="#LINK_c2d0a5b6-befc-4a12-bb22-f0dd304ae332">2.2</linkHtml>)</paragraph>
                           </item>
                           <item>
                              <content styleCode="underline">Maintenance of anesthesia: </content>Increments of one-half to the full induction dose may be repeated as needed (<linkHtml href="#LINK_c2d0a5b6-befc-4a12-bb22-f0dd304ae332">2.2</linkHtml>). Adjust the dose according to the patient's anesthetic needs and whether an additional anesthetic agent is employed. (<linkHtml href="#LINK_c2d0a5b6-befc-4a12-bb22-f0dd304ae332">2.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Supplement to other anesthetic agents</content>: The regimen of a reduced dose of KETALAR supplemented with diazepam can be used to produce balanced anesthesia by combination with other agents. (<linkHtml href="#LINK_c2d0a5b6-befc-4a12-bb22-f0dd304ae332">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_880f96be-13fc-40f8-a70c-a44229a31a72">
                     <id root="88fe5a2e-8a80-4293-b83c-939399a107e0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1
Important Dosage and Administration Information</title>
                     <text>
                        <paragraph>KETALAR should be administered by or under the direction of physicians experienced in the administration of general anesthetics, maintenance of a patent airway, and oxygenation and ventilation.  Continuously monitor vital signs in patients receiving KETALAR.</paragraph>
                        <paragraph>Emergency airway equipment must be immediately available.</paragraph>
                        <paragraph>Do not administer the 100 mg/mL concentration of KETALAR intravenously without proper dilution <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_9f876c31-bbca-477d-8ffc-27c069156818">2.3</linkHtml>)]</content>. Must be used immediately after dilution.</paragraph>
                        <paragraph>While some degree of airway protection may be afforded due to active laryngeal-pharyngeal reflexes, vomiting and aspiration may occur with KETALAR.  KETALAR is not recommended for use in patients who have not followed <content styleCode="italics">nil per os </content>guidelines. </paragraph>
                        <paragraph>Due to the potential for salivation during KETALAR administration, administer an antisialagogue prior to induction of anesthesia.</paragraph>
                        <paragraph>In individuals with a history of chronic ketamine use for off-label indications, there have been case reports of genitourinary pain that may be related to the ketamine treatment, not the underlying condition <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#www.splportal.comLINK_675bbff7-5b49-4045-b686-aa2dff5fcb57">6</linkHtml>)]</content>. Consider cessation of ketamine if genitourinary pain continues in the setting of other genitourinary symptoms.</paragraph>
                     </text>
                     <effectiveTime value="20220330"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c2d0a5b6-befc-4a12-bb22-f0dd304ae332">
                     <id root="7726ef1e-53a4-430c-9fa3-240f48398da3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2  Recommended
Dosage and Administration</title>
                     <text>
                        <paragraph>The KETALAR dosage must be individualized and titrated to the desired clinical effect.</paragraph>
                        <paragraph>If a longer duration of effect is desired, additional increments can be administered intravenously or intramuscularly to maintain anesthesia. However, a higher total dose will result in a longer time to complete recovery.</paragraph>
                     </text>
                     <effectiveTime value="20220330"/>
                     <component>
                        <section ID="LINK_3617ce0d-35d8-43ef-96fc-07c47c630c52">
                           <id root="37443f2f-4d7f-40bb-90e2-8b46b43b592a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Induction
of Anesthesia</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Intravenous Route: </content>The initial dose of KETALAR administered intravenously may range from 1 mg/kg to 4.5 mg/kg. The average amount required to produce 5 to 10 minutes of surgical anesthesia within 30 seconds following injection is 2 mg/kg. Administer KETALAR slowly (i.e., over a period of 60 seconds). Rapid administration may result in respiratory depression and enhanced vasopressor response. The induction dose may be administered as an intravenous infusion at a rate of 0.5 mg/kg/min. </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Intramuscular Route</content>: The initial dose of KETALAR administered intramuscularly may range from 6.5 to 13 mg/kg. A dose of 9 to 13 mg/kg usually produces surgical anesthesia within 3 to 4 minutes following injection, with the anesthetic effect usually lasting 12 to 25 minutes. Administer a benzodiazepine, if clinically indicated, for the prevention of neuropsychological manifestations during emergence from anesthesia.  </paragraph>
                           </text>
                           <effectiveTime value="20220330"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_d5d482f6-bb25-41ce-99bc-c52c756238ad">
                           <id root="0827a037-0ef2-4e6a-9c39-f9b418f1c116"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Maintenance
of Anesthesia</content>
                           </title>
                           <text>
                              <paragraph>Adjust the maintenance dose according to the patient's anesthetic needs and whether an additional anesthetic agent is administered. </paragraph>
                              <paragraph>Repeat increments of one-half to the full induction dose as needed for maintenance of anesthesia. Purposeless and tonic-clonic movements of extremities may occur during the course of ketamine anesthesia. These movements do not imply a light plane and are not indicative of the need for additional doses of the anesthetic. </paragraph>
                              <paragraph>KETALAR given by slow microdrip infusion technique at a dose of 0.1 to 0.5 mg/minute will maintain general anesthesia in adult patients induced with KETALAR. Augment KETALAR with an intravenous benzodiazepine for the prevention of neuropsychological manifestations during emergence. </paragraph>
                           </text>
                           <effectiveTime value="20220330"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_e88750dc-e105-4170-9519-84235da3b3b6">
                           <id root="200d106d-d047-462f-af77-997f3a386af3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Supplement
to Other Anesthetic Agents</content>
                           </title>
                           <text>
                              <paragraph>KETALAR can be administered to supplement other general and local anesthetic agents.  Continuously monitor patients for changes in respiratory and hemodynamic parameters. </paragraph>
                              <paragraph>
                                 <content styleCode="bold"> </content>A reduced dose of KETALAR can be used to produce balanced anesthesia when used in combination with other anesthetic agents.</paragraph>
                           </text>
                           <effectiveTime value="20220330"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9f876c31-bbca-477d-8ffc-27c069156818">
                     <id root="47755417-2ca2-44cf-99c0-915940dcd68b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3  Preparation
of Dilution</title>
                     <text>
                        <paragraph>KETALAR is a clear, colorless sterile solution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Discard if product is discolored or contains particulate matter.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Induction of Anesthesia</content>
                           </content>: Do not intravenously inject the 100 mg/mL concentration of KETALAR without proper dilution. Dilute KETALAR with an equal volume of either Sterile Water for injection, USP, 0.9% Sodium Chloride Injection, USP (Normal Saline), or 5% Dextrose in Water. Use immediately after dilution.</paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Maintenance of Anesthesia</content>
                           </content>: To prepare a dilute solution containing 1 mg of ketamine per mL, aseptically transfer 10 mL from a 50 mg per mL vial or 5 mL from a 100 mg per mL vial to 500 mL of 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP (Normal Saline) and mix well. The resultant solution will contain 1 mg of ketamine per mL. Use immediately after dilution.</paragraph>
                        <paragraph>When fluid restriction is required, KETALAR can be added to a 250 mL infusion as described above to provide a KETALAR concentration of 2 mg/mL. </paragraph>
                        <paragraph>KETALAR 10 mg/mL vials are not recommended for dilution. </paragraph>
                     </text>
                     <effectiveTime value="20220330"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_0546d6c9-f9bb-4fc9-bc50-4c98fa61c592">
               <id root="957e5a62-874e-4fb6-b8c8-7c456e3a6ad1"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>KETALAR injection is a clear, colorless, sterile solution available in multiple-dose vials containing either 10 mg ketamine base (equivalent to 11.53 mg ketamine hydrochloride), 50 mg ketamine base (equivalent to 57.67 mg ketamine hydrochloride) or 100 mg ketamine base (equivalent to 115.33 mg ketamine hydrochloride). </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>200 mg/20 mL (10 mg/mL) </item>
                     <item>500 mg/10 mL (50 mg/mL) </item>
                     <item>500 mg/5 mL (100 mg/mL) </item>
                  </list>
               </text>
               <effectiveTime value="20220330"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection:  200 mg/20 mL (10 mg/mL), 500 mg/10 mL (50 mg/mL), and 500 mg/5 mL (100 mg/mL) multiple-dose vials (<linkHtml href="#LINK_e1f71715-c1f6-44f3-b581-adb1426b4831">3</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_fbdf7c22-c16e-4e42-90d9-18e1f666a1d8">
               <id root="c718b925-77c9-4884-8be0-f22fa08b3c81"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>KETALAR is contraindicated in patients for whom a significant elevation of blood pressure would constitute a serious hazard <content styleCode="italics">[see Warnings and Precautions(<linkHtml href="#www.splportal.comLINK_122e1c3d-57ed-44a6-8317-80378f166ffc">5.1</linkHtml>)]</content>.</item>
                     <item>KETALAR is contraindicated in patients with known hypersensitivity to ketamine or to any excipient <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#www.splportal.comLINK_675bbff7-5b49-4045-b686-aa2dff5fcb57">6</linkHtml>)]</content>.</item>
                  </list>
               </text>
               <effectiveTime value="20220330"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>In patients for whom a significant elevation of blood pressure would be a serious hazard (<linkHtml href="#LINK_69a67555-6e7a-4562-b4f1-537f19bf6e8f">4</linkHtml>).</item>
                           <item>Known hypersensitivity to ketamine or to any excipient (<linkHtml href="#LINK_69a67555-6e7a-4562-b4f1-537f19bf6e8f">4</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_5b4f988b-ad18-4507-9394-bd0b45858c0b">
               <id root="d1d1a0a9-c20a-4a7d-9d29-d15d59c8e788"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20220330"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Hemodynamic Instability:</content> Monitor vital signs and cardiac function during KETALAR administration. (<linkHtml href="#LINK_122e1c3d-57ed-44a6-8317-80378f166ffc">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Emergence Reactions:</content> Postoperative confusional states may occur during the recovery period. Reduce by minimizing verbal, tactile, and visual stimulation of the patient. (<linkHtml href="#LINK_710d2121-0f26-43ed-a600-b2f68a364b75">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Risk of Respiratory Depression:</content> May occur with overdosage or too rapid a rate of administration. Maintain adequate oxygenation and ventilation. (<linkHtml href="#LINK_7a5d5037-ae83-4ec3-a51a-19263c01d16e">5.3</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Risks of KETALAR alone for Procedures of the Pharynx, Larynx, or Bronchial Tree</content>: Pharyngeal and laryngeal reflexes are not suppressed with KETALAR when it is used alone. Avoid use as a sole anesthetic agent in surgery or diagnostic procedures of the pharynx, larynx, or bronchial tree. Muscle relaxants may be required. (<linkHtml href="#LINK_db7b1b0e-6c1f-49a0-8861-48aae8075467">5.4</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Pediatric Neurotoxicity:</content> Long-term cognitive deficits may occur when used for longer than 3 hours in children ≤3 years (<linkHtml href="#LINK_df5cfdae-63db-4348-928a-864b45d3b013">5.5</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_122e1c3d-57ed-44a6-8317-80378f166ffc">
                     <id root="3dde83f5-bb86-46ff-a1c2-2329edb85835"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1  Hemodynamic Instability</title>
                     <text>
                        <paragraph>Transient increases in blood pressure, heart rate, and cardiac index are frequently observed following administration of KETALAR. Decreases in blood pressure and heart rate, arrhythmias, and cardiac decompensation have also been observed. Monitor vital signs and cardiac function during KETALAR administration. KETALAR is contraindicated in patients for whom a significant elevation of blood pressure would constitute a serious hazard <content styleCode="italics">[see Contraindications (<linkHtml href="#www.splportal.comLINK_69a67555-6e7a-4562-b4f1-537f19bf6e8f">4</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20220330"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_710d2121-0f26-43ed-a600-b2f68a364b75">
                     <id root="26fbb5aa-0dc7-4176-9715-d1dfb5db5429"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2  Emergence
Reactions</title>
                     <text>
                        <paragraph>Emergence delirium (postoperative confusional states or agitation) has occurred in approximately 12% of patients during the recovery period, and the duration is generally a few hours. The neuropsychological manifestations vary in severity between pleasant dream-like states, vivid imagery, hallucinations, and emergence delirium. In some cases, these states have been accompanied by confusion, excitement, and irrational behavior, which have been recalled as unpleasant experiences. No residual psychological effects are known to have resulted from use of KETALAR during induction and maintenance of anesthesia. </paragraph>
                        <paragraph>Intramuscular administration results in a lower incidence of emergence reactions. </paragraph>
                        <paragraph>The incidence of psychological manifestations during emergence, particularly dream-like observations and emergence delirium, may be reduced by using lower recommended dosages of KETALAR in conjunction with an intravenous benzodiazepine during induction and maintenance of anesthesia <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_9f876c31-bbca-477d-8ffc-27c069156818">2.3</linkHtml>)]</content>. Also, these reactions may be reduced if verbal, tactile, and visual stimulation of the patient is minimized during the recovery period. This does not preclude the monitoring of vital signs. </paragraph>
                     </text>
                     <effectiveTime value="20220330"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7a5d5037-ae83-4ec3-a51a-19263c01d16e">
                     <id root="d8491300-69fa-4581-8221-43ce8b26a557"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3  Respiratory Depression</title>
                     <text>
                        <paragraph>Respiratory depression may occur with overdosage or a rapid rate of administration of KETALAR. Maintain adequate oxygenation and ventilation. </paragraph>
                     </text>
                     <effectiveTime value="20220330"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_db7b1b0e-6c1f-49a0-8861-48aae8075467">
                     <id root="090a6614-78f6-496f-8021-cd8a7b53c3c6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4  Risks of Ketalar Alone for Procedures of the
Pharynx, Larynx, or Bronchial Tree</title>
                     <text>
                        <paragraph>KETALAR does not suppress pharyngeal and laryngeal reflexes. Avoid KETALAR administration as a sole anesthetic agent during procedures of the pharynx, larynx, or bronchial tree, including mechanical stimulation of the pharynx. Muscle relaxants may be required for successful completion of procedures of the pharynx, larynx, or bronchial tree.</paragraph>
                     </text>
                     <effectiveTime value="20220330"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_df5cfdae-63db-4348-928a-864b45d3b013">
                     <id root="5241f0ec-9a4f-4386-b0a0-a8d502384576"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5  Pediatric
Neurotoxicity</title>
                     <text>
                        <paragraph>Published animal studies demonstrate that the administration of anesthetic and sedation drugs that block NMDA receptors and/or potentiate GABA activity increase neuronal apoptosis in the developing brain and result in long-term cognitive deficits when used for longer than 3 hours. The clinical significance of these findings is not clear. However, based on the available data, the window of vulnerability to these changes is believed to correlate with exposures in the third trimester of gestation through the first several months of life, but may extend out to approximately three years of age in humans<content styleCode="italics"> [see Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_e475f237-3e80-443e-8922-4a4c39273af8">8.1</linkHtml>, <linkHtml href="#www.splportal.comLINK_916f38a7-8120-4f83-a121-cb8dc49742ff">8.4</linkHtml>), Nonclinical Toxicology (<linkHtml href="#www.splportal.comLINK_de2d5267-3b62-4daf-86a7-621501868029">13.2</linkHtml>)].</content>
                        </paragraph>
                        <paragraph>Some published studies in children suggest that similar deficits may occur after repeated or prolonged exposures to anesthetic agents early in life and may result in adverse cognitive or behavioral effects. These studies have substantial limitations, and it is not clear if the observed effects are due to the anesthetic/sedation drug administration or other factors such as the surgery or underlying illness.</paragraph>
                        <paragraph>Anesthetic and sedation drugs are a necessary part of the care of children needing surgery, other procedures, or tests that cannot be delayed, and no specific medications have been shown to be safer than any other. Decisions regarding the timing of any elective procedures requiring anesthesia should take into consideration the benefits of the procedure weighed against the potential risks.</paragraph>
                     </text>
                     <effectiveTime value="20220330"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ab51a884-c0e0-47f2-ad3f-3e6d4d57fe53">
                     <id root="740fe9e0-b9e3-402b-b196-f339808a82a3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Drug-Induced Liver Injury</title>
                     <text>
                        <paragraph>Ketamine administration is associated with hepatobiliary dysfunction (most often a cholestatic pattern), with recurrent use (e.g., misuse/abuse or medically supervised unapproved indications). Biliary duct dilatation with or without evidence of biliary obstruction has also been reported with recurrent use. Obtain baseline LFTs, including alkaline phosphatase and gamma glutamyl transferase, in patients receiving ketamine as part of a treatment plan that utilizes recurrent dosing. Monitor those receiving recurrent ketamine at periodic intervals during treatment.</paragraph>
                     </text>
                     <effectiveTime value="20220330"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_a7d6d62d-f551-48a1-97d0-4b32949462fa">
                     <id root="25c8dfab-4cd5-40f1-bd37-df2598b3b5b3"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7  Increase in Cerebrospinal Fluid Pressure</title>
                     <text>
                        <paragraph>An increase in intracranial pressure has been reported following administration of ketamine hydrochloride. Patients with elevated intracranial pressure should be in a monitored setting with frequent neurologic assessments. </paragraph>
                     </text>
                     <effectiveTime value="20220330"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e41c199c-05e1-462f-a7a4-d9aac7794f60">
                     <id root="32f09546-da1f-4a1a-9e35-99c19c1a13ec"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8  Drug Interactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Theophylline or Aminophylline</content>: Concomitant administration of KETALAR and theophylline or aminophylline may lower the seizure threshold <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_d8475d0e-a25a-4c42-84b1-3952f21b1005">7.1</linkHtml>)]</content>. Consider using an alternative to KETALAR in patients receiving theophylline or aminophylline.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Sympathomimetics and Vasopressin</content>: Sympathomimetics and vasopressin may enhance the sympathomimetic effects of ketamine<content styleCode="italics"> [see Drug Interactions (<linkHtml href="#www.splportal.comLINK_d86c8937-bced-4a29-9c48-f36797dd4bde">7.2</linkHtml>)]</content>. Closely monitor vital signs when KETALAR and sympathomimetics or vasopressin are co-administered and consider dose adjustment individualized to the patient’s clinical situation.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Benzodiazepines, Opioid Analgesics, or Other CNS Depressants</content>
                        </paragraph>
                        <paragraph>Concomitant use of ketamine with opioid analgesics, benzodiazepines, or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_801e5e0f-b683-48d3-bd41-62ba89eb65be">7.3</linkHtml>)]</content>. Closely monitor neurological status and respiratory parameters, including respiratory rate and pulse oximetry, when KETALR and opioid analgesics, benzodiazepines, or other CNS depressants are co-administered. Consider dose adjustment individualized to the patient’s clinical situation.</paragraph>
                     </text>
                     <effectiveTime value="20220330"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_5928e765-5c28-429b-9232-a8c2bfe229ed">
               <id root="3b505eb7-c7e0-49fc-85e5-710b3bc79b34"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Hemodynamic Instability <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_122e1c3d-57ed-44a6-8317-80378f166ffc">5.1</linkHtml>)]</content>
                     </item>
                     <item>Emergence Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_710d2121-0f26-43ed-a600-b2f68a364b75">5.2</linkHtml>)]</content>
                     </item>
                     <item>Respiratory Depression <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_7a5d5037-ae83-4ec3-a51a-19263c01d16e">5.3</linkHtml>)]</content>
                     </item>
                     <item>Pediatric Neurotoxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_df5cfdae-63db-4348-928a-864b45d3b013">5.5</linkHtml>)]</content>
                     </item>
                     <item>Drug-Induced Liver Injury <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_ab51a884-c0e0-47f2-ad3f-3e6d4d57fe53">5.6</linkHtml>)]</content>
                     </item>
                  </list>
                  <paragraph>The following adverse reactions associated with the use of KETALAR were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Cardiovascular disorders</content>: Elevated blood pressure, heart rate, and cardiac index; decreases in blood pressure and heart rate; arrhythmias; cardiac decompensation (in patients with suspected catecholamine depletion).  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Eye disorders</content>: Diplopia, nystagmus, elevation in intraocular pressure. </paragraph>
                  <paragraph>
                     <content styleCode="italics">Gastrointestinal disorders</content>: Anorexia, nausea, vomiting, hepatobiliary dysfunction. Biliary duct dilatation with or without evidence of biliary obstruction has been reported with recurrent use (e.g., misuse/abuse or medically supervised unapproved indications).</paragraph>
                  <paragraph>
                     <content styleCode="italics">Administration site disorders</content>: Local pain and exanthema at the injection site.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Immune system disorders</content>: Anaphylaxis. </paragraph>
                  <paragraph>
                     <content styleCode="italics">Neurologic disorders</content>: Emergence reactions (post-operative delirium), <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_710d2121-0f26-43ed-a600-b2f68a364b75">5.2</linkHtml>)].</content> During administration, enhanced muscle tone and spasms (resembling a partial motor or generalized motor seizure). </paragraph>
                  <paragraph>
                     <content styleCode="italics">Psychiatric disorders</content>: Adverse psychiatric events have occurred and/or persisted days to weeks after ketamine exposure.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Renal and urinary disorders:</content> In individuals with history of chronic ketamine use or abuse, lower urinary tract and bladder symptoms including dysuria, increased urinary frequency, urgency, urge incontinence, and hematuria have been reported <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#www.splportal.comLINK_880f96be-13fc-40f8-a70c-a44229a31a72">2.1</linkHtml>)]</content>. In addition, diagnostic studies performed to assess the cause of these symptoms have reported cystitis (including cystitis non-infective, cystitis interstitial, cystitis ulcerative, cystitis erosive and cystitis hemorrhagic) as well as hydronephrosis and reduced bladder capacity. </paragraph>
                  <paragraph>
                     <content styleCode="italics">Respiratory disorders</content>: Respiratory depression and apnea following rapid intravenous administration of high doses of KETALAR; laryngospasm, and airway obstruction. </paragraph>
                  <paragraph>
                     <content styleCode="italics">Skin and subcutaneous tissue disorders</content>: Transient erythema and/or morbilliform rash</paragraph>
               </text>
               <effectiveTime value="20220330"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions are emergence reactions and elevated blood pressure and pulse (<linkHtml href="#LINK_675bbff7-5b49-4045-b686-aa2dff5fcb57">6</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="bold"> </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Endo at 1-800-828-9393 or FDA at 1-800-FDA-1088 or </content>
                           <content styleCode="bold">
                              <linkHtml href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>
                           </content>
                           <content styleCode="bold">. </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_a9f48fb2-b731-494a-8f27-830e4f3be392">
               <id root="c90de70b-bed4-40e1-bbd4-5f680e90456a"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text/>
               <effectiveTime value="20220330"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Theophylline or Aminophylline</content>: Do not co-administer with KETALAR as concomitant use may lower the seizure threshold (<linkHtml href="#LINK_d8475d0e-a25a-4c42-84b1-3952f21b1005">7.1</linkHtml>). </paragraph>
                        <paragraph>
                           <content styleCode="underline">Sympathomimetics and Vasopressin</content>: Closely monitor vital signs when co-administered with KETALAR. Consider dose adjustment individualized to the patient’s clinical situation (<linkHtml href="#LINK_d86c8937-bced-4a29-9c48-f36797dd4bde">7.2</linkHtml>).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Benzodiazepines, Opioid Analgesics, or other CNS Depressants</content>: Concomitant use may result in profound sedation, respiratory depression, coma, or death. Concomitant use of opioid analgesics may prolong recovery time. (<linkHtml href="#LINK_801e5e0f-b683-48d3-bd41-62ba89eb65be">7.3</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_d8475d0e-a25a-4c42-84b1-3952f21b1005">
                     <id root="7300ec97-f749-4461-9146-b5f067e4c227"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1  Theophylline
or Aminophylline</title>
                     <text>
                        <paragraph>Concomitant administration of KETALAR and theophylline or aminophylline may lower the seizure threshold. Consider using an alternative to KETALAR in patients receiving theophylline or aminophylline.</paragraph>
                     </text>
                     <effectiveTime value="20220330"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d86c8937-bced-4a29-9c48-f36797dd4bde">
                     <id root="9d71be8e-c91d-4af6-8ce0-32a394542964"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2  Sympathomimetics
and Vasopressin</title>
                     <text>
                        <paragraph>Sympathomimetics and vasopressin may enhance the sympathomimetic effects of ketamine. Closely monitor vital signs when KETALAR and sympathomimetics or vasopressin are co-administered and consider dose adjustment individualized to the patient’s clinical situation.</paragraph>
                     </text>
                     <effectiveTime value="20220330"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_801e5e0f-b683-48d3-bd41-62ba89eb65be">
                     <id root="a03437f7-fc8b-4540-a0ac-7446ac6bcbc1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3  Benzodiazepines,
Opioid Analgesics, Or Other CNS Depressants</title>
                     <text>
                        <paragraph>Concomitant use of ketamine with opioid analgesics, benzodiazepines, or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_e41c199c-05e1-462f-a7a4-d9aac7794f60">5.8</linkHtml>)]</content>. </paragraph>
                        <paragraph>Opioid analgesics administered concomitantly with KETALAR may prolong time to complete recovery from anesthesia.</paragraph>
                     </text>
                     <effectiveTime value="20220330"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_620c01ec-d194-46f0-b8c7-70fd7f92c264">
               <id root="5c1478c1-7994-4182-9dfb-c1a159ddf25e"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20220330"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Pregnancy</content>: Animal data show that KETALAR may cause harm to the fetus; avoid use during pregnancy, labor, and delivery (<linkHtml href="#LINK_e475f237-3e80-443e-8922-4a4c39273af8">8.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_9a6bb37c-666f-46fb-be19-aa7e819e1557">
                     <id root="ed91dded-7af6-4227-85af-b6433c886047"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20220330"/>
                     <component>
                        <section ID="LINK_a5c0537f-c710-496b-b6e0-9c679ee9f51e">
                           <id root="e189b04e-ec7b-4819-a3a2-8b5d861438c4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Risk Summary</content>
                           </title>
                           <text>
                              <paragraph>There are no adequate and well-controlled studies of KETALAR in pregnant women. In animal reproduction studies in rats developmental delays (hypoplasia of skeletal tissues) were noted at 0.3 times the human intramuscular dose of 10 mg/kg. In rabbits, developmental delays and increased fetal resorptions were noted at 0.6 times the human dose. Published studies in pregnant primates demonstrate that the administration of anesthetic and sedation drugs that block NMDA receptors and/or potentiate GABA activity during the period of peak brain development increases neuronal apoptosis in the developing brain of the offspring when used for longer than 3 hours. There are no data on pregnancy exposures in primates corresponding to periods prior to the third trimester in humans.</paragraph>
                              <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20220330"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_dc0b391c-3263-471b-9c39-8e4a67efa955">
                           <id root="98203138-c889-4d0f-b4bb-aac60fe88a4d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Clinical Considerations</content>
                           </title>
                           <text>
                              <paragraph>KETALAR use in pregnancy, including obstetrics (either vaginal or abdominal delivery), is not recommended because safe use has not been established <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_df5cfdae-63db-4348-928a-864b45d3b013">5.5</linkHtml>), Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_916f38a7-8120-4f83-a121-cb8dc49742ff">8.4</linkHtml>) and Nonclinical Toxicology (<linkHtml href="#www.splportal.comLINK_de2d5267-3b62-4daf-86a7-621501868029">13.2</linkHtml>)]</content>. </paragraph>
                           </text>
                           <effectiveTime value="20220330"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_693ad2d0-2f42-44c7-83e7-ca022ec9c26a">
                           <id root="4b166c2b-b02f-48e2-8200-1b545a2cb09c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Data</content>
                           </title>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Animal Data</content>
                              </paragraph>
                              <paragraph>Pregnant rats were treated intramuscularly with 20 mg/kg ketamine (0.3 times the human dose of 10 mg/kg IM based on body surface area) on either Gestation Days 6 to 10 or Gestation Days 11 to 15. Ketamine treatment produced an increased incidence of hypoplastic skull, phalanges, and sternebrae in the pups.</paragraph>
                              <paragraph>Pregnant rabbits were treated intramuscularly with 20 mg/kg ketamine (0.6 times the human dose of 10 mg/kg IM based on body surface area) on either Gestation Days 6 to 10 or Gestation Days 11 to 15. An increase in resorptions and skeletal hypoplasia of the fetuses were noted. Additional pregnant rabbits were treated intramuscularly with a single dose 60 mg/kg (1.9 times the human dose of 10 mg/kg IM based on body surface area) on Gestation Day 6 only. Skeletal hypoplasia was reported in the fetuses.</paragraph>
                              <paragraph>In a study where pregnant rats were treated intramuscularly with 20 mg/kg ketamine (0.3 times the human dose of 10 mg/kg IM based on body surface area) from Gestation Day 18 to 21. There was a slight increase in incidence of delayed parturition by one day in treated dams of this group. No adverse effects on the litters or pups were noted; however, learning and memory assessments were not completed. </paragraph>
                              <paragraph>Three (3) pregnant beagle dogs were treated intramuscularly with 25 mg/kg ketamine (1.3 times the human dose of 10 mg/kg IM based on body surface area) twice weekly for the three weeks of the first, second, and third trimesters of pregnancy, respectively, without the development of adverse effects in the pups. </paragraph>
                              <paragraph>In a published study in primates, administration of an anesthetic dose of ketamine for 24 hours on Gestation Day 122 increased neuronal apoptosis in the developing brain of the fetus. In other published studies, administration of either isoflurane or propofol for 5 hours on Gestation Day 120 resulted in increased neuronal and oligodendrocyte apoptosis in the developing brain of the offspring. With respect to brain development, this time period corresponds to the third trimester of gestation in the human. The clinical significance of these findings is not clear; however, studies in juvenile animals suggest neuroapoptosis correlates with long-term cognitive deficits<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_df5cfdae-63db-4348-928a-864b45d3b013">5.5</linkHtml>), Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_916f38a7-8120-4f83-a121-cb8dc49742ff">8.4</linkHtml>), and Nonclinical Toxicology (<linkHtml href="#www.splportal.comLINK_de2d5267-3b62-4daf-86a7-621501868029">13.2</linkHtml>)]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20220330"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ca47e416-5831-4010-9d2d-8974b5f3daf3">
                     <id root="693d1168-9ec2-47bb-b529-440b8a4b0f72"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients below the age of 16 have not been established. </paragraph>
                        <paragraph>Published juvenile animal studies demonstrate that the administration of anesthetic and sedation drugs, such as KETALAR, that either block NMDA receptors or potentiate the activity of GABA during the period of rapid brain growth or synaptogenesis, results in widespread neuronal and oligodendrocyte cell loss in the developing brain and alterations in synaptic morphology and neurogenesis. Based on comparisons across species, the window of vulnerability to these changes is believed to correlate with exposures in the third trimester of gestation through the first several months of life but may extend out to approximately 3 years of age in humans.</paragraph>
                        <paragraph>In primates, exposure to 3 hours of ketamine that produced a light surgical plane of anesthesia did not increase neuronal cell loss, however, treatment regimens of 5 hours or longer of isoflurane increased neuronal cell loss. Data from isoflurane-treated rodents and ketamine-treated primates suggest that the neuronal and oligodendrocyte cell losses are associated with prolonged cognitive deficits in learning and memory. The clinical significance of these nonclinical findings is not known, and healthcare providers should balance the benefits of appropriate anesthesia in neonates and young children who require procedures with the potential risks suggested by the nonclinical data <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_df5cfdae-63db-4348-928a-864b45d3b013">5.5</linkHtml>), Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_e475f237-3e80-443e-8922-4a4c39273af8">8.1</linkHtml>), and Nonclinical Toxicology (<linkHtml href="#www.splportal.comLINK_de2d5267-3b62-4daf-86a7-621501868029">13.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20220330"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_ec14c087-21d2-4394-ab86-f7f58fe8a02d">
                     <id root="cb761d05-cfdc-4b5f-bb51-84329393bc55"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of ketamine hydrochloride did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. </paragraph>
                     </text>
                     <effectiveTime value="20220330"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_60097ff6-3d6e-4818-bb61-da310767a498">
               <id root="cb39589b-dc4e-474d-8e74-81acc3f1a914"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>9 DRUG ABUSE AND DEPENDENCE</title>
               <effectiveTime value="20220330"/>
               <component>
                  <section ID="LINK_51139d64-8742-4eea-bfa1-ac6ed65a276d">
                     <id root="5f1cde32-c657-4ec8-9e0f-fb59573dd62d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>9.1 
Controlled
Substance</title>
                     <text>
                        <paragraph>KETALAR contains ketamine, a Schedule III controlled substance under the Controlled Substance Act. </paragraph>
                     </text>
                     <effectiveTime value="20220330"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f3edd320-24eb-4a4d-9886-bf0ffe64cbf5">
                     <id root="fae7fc73-f46d-47dc-94b4-bd503d964685"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>9.2  Abuse</title>
                     <text>
                        <paragraph>Individuals with a history of drug abuse or dependence may be at greater risk for abuse and misuse of KETALAR. Abuse is the intentional, non-therapeutic use of a drug, even once, for its psychological or physiological effects. Misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed.</paragraph>
                        <paragraph>In a context of drug abuse, KETALAR may produce a variety of symptoms including anxiety, dysphoria, disorientation, insomnia, flashback, hallucinations, and feelings of floating, detachment and being “spaced out”.</paragraph>
                        <paragraph>Recurrent high-dose ketamine misuse or abuse may be associated with memory and/or attention impairment. </paragraph>
                     </text>
                     <effectiveTime value="20220330"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_67dbb26c-a9eb-4cb4-9199-75259d6bcc09">
                     <id root="91583bcc-47ba-4c46-818c-a8eef66e83e8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>9.3 
Dependence</title>
                     <text>
                        <paragraph>Physical dependence has been reported with prolonged use of ketamine. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or significant dosage reduction of a drug. Withdrawal symptoms have been reported after the discontinuation of frequently used (more than weekly), large doses of ketamine for long periods of time. Reported symptoms of withdrawal associated with daily intake of large doses of ketamine include craving, fatigue, poor appetite, and anxiety. </paragraph>
                        <paragraph>Tolerance has been reported with prolonged use of ketamine. Tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose).</paragraph>
                     </text>
                     <effectiveTime value="20220330"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_d0a8769d-e081-44f1-a5a8-d06f9122ab72">
               <id root="80af1bce-eee6-4985-922e-0eaac7e1809c"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Changes in heart rate and blood pressure, respiratory depression, and apnea may occur with overdosage or by a rapid rate of administration of KETALAR.  Monitor patients for clinically relevant changes in heart rate and blood pressure. Assisted ventilation, including mechanical ventilation, may be required.</paragraph>
                  <paragraph>In cases of unintentional overdose of KETALAR (up to ten times that usually required), patients had a prolonged but complete recovery. </paragraph>
               </text>
               <effectiveTime value="20220330"/>
            </section>
         </component>
         <component>
            <section ID="LINK_4e30b721-fbd5-4edf-a424-bd7aea0fe161">
               <id root="00723784-2fee-46d4-ae8e-d5a86124ea68"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>KETALAR (ketamine hydrochloride) injection, for intravenous or intramuscular use, contains ketamine, a nonbarbiturate general anesthetic. Ketamine hydrochloride, USP is a white crystalline powder and has a molecular formula of C<sub>13</sub>H<sub>16</sub>ClNO•HCl and a molecular weight of 274.19. The chemical name for ketamine hydrochloride is (±)-2-(<content styleCode="italics">o</content>-Chlorophenyl)-2-(methylamino)cyclohexanone hydrochloride. The chemical structure of ketamine hydrochloride is:</paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="MM1"/>
                     </content>
                  </paragraph>
                  <paragraph>It is formulated as a slightly acidic (pH 3.5-5.5) sterile solution for intravenous or intramuscular injection. Each milliliter (mL) of the multiple-dose vials contain either 10 mg ketamine base (equivalent to 11.53 mg ketamine hydrochloride), 50 mg ketamine base (equivalent to 57.67 mg ketamine hydrochloride) or 100 mg ketamine base (equivalent to 115.33 mg ketamine hydrochloride) and not more than 0.10 mg/mL benzethonium chloride added as a preservative in water for injection. The 10 mg/mL solution has been made isotonic with 6.60 mg sodium chloride. </paragraph>
               </text>
               <effectiveTime value="20220330"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>ketamine hydrochloride</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ketalar-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_81878798-4531-4611-bfcc-5feced60c400">
               <id root="acd5fd97-251a-4b2a-b944-ae929043a9e5"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20220330"/>
               <component>
                  <section ID="LINK_6902b24b-39fc-495f-ab48-c4ef4fa86a74">
                     <id root="bd80d585-8f53-48f2-89f2-d9043efd78f3"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>KETALAR, a racemic mixture of ketamine, is a non-selective, non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, an ionotropic glutamate receptor. The major circulating metabolite of ketamine (norketamine) demonstrated activity at the same receptor with less affinity. Norketamine is about 1/3 as active as ketamine in reducing halothane requirements (MAC) of the rat. </paragraph>
                     </text>
                     <effectiveTime value="20220330"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_51d0c108-8072-4185-a6ad-bbc1085416f0">
                     <id root="ae7b39da-e6da-46bf-bbf4-13a5c00c2f05"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text/>
                     <effectiveTime value="20220330"/>
                     <component>
                        <section ID="LINK_67ed3a94-7e46-4040-93d7-920b48c8ec1c">
                           <id root="1eda2cf3-06b6-4391-8cf6-d1eb1994b7e4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Nervous System</content>
                           </title>
                           <text>
                              <paragraph>Ketamine is a rapidly-acting general anesthetic producing a dissociative anesthetic state characterized by profound analgesia, normal pharyngeal-laryngeal reflexes, normal or slightly enhanced skeletal muscle tone, cardiovascular and respiratory stimulation, and occasionally a transient and minimal respiratory depression. The mechanism of action is primarily due to antagonism of N-methyl-D-aspartate (NMDA receptors) in the central nervous system. </paragraph>
                              <paragraph>Ketamine can produce nystagmus with pupillary dilation, salivation, lacrimation, and spontaneous limb movements with increased muscle tone through indirect sympathomimetic activity. Ketamine produces analgesia. Ketamine-induced emergence delirium can be reduced with benzodiazepines.</paragraph>
                           </text>
                           <effectiveTime value="20220330"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_ed515935-8f8e-4096-8ba8-6ec2f69a2fcc">
                           <id root="614e1ac2-f0ae-4299-aa72-11e1c241b262"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Cardiovascular System</content>
                           </title>
                           <text>
                              <paragraph>Ketamine increases blood pressure, heart rate, and cardiac output. Cardiovascular effects of ketamine are indirect and believed to be mediated by inhibition of both central and peripheral catecholamine reuptake. Elevation of blood pressure reaches a maximum within a few minutes of injection and usually returns to preanesthetic values within 15 minutes. In the majority of cases, the systolic and diastolic blood pressure peaks from 10% to 50% above preanesthetic levels shortly after induction of anesthesia, but the elevation can be higher or longer in individual cases. </paragraph>
                           </text>
                           <effectiveTime value="20220330"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_3f5038bc-1b17-4afb-8f39-619effd8a7f6">
                           <id root="5899e3ff-7103-460e-aef9-92954fe7dff1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Respiratory System</content>
                           </title>
                           <text>
                              <paragraph>Ketamine is a potent bronchodilator suitable for anesthetizing patients at high risk for bronchospasm.</paragraph>
                           </text>
                           <effectiveTime value="20220330"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_0815c71e-1e33-4316-a18d-bf23d1aaeb7b">
                     <id root="59ad6dbf-2fb1-4bef-a488-953d815dfccd"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <effectiveTime value="20220330"/>
                     <component>
                        <section ID="LINK_d6621e13-854e-4c9e-8ea3-6b8914f1924e">
                           <id root="ba6ada42-d868-4b1b-905d-76f3ec75b0af"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Distribution</content>
                              <br/>
                           </title>
                           <text>
                              <paragraph>Following intravenous administration, the ketamine concentration has an initial slope (alpha phase) lasting about 45 minutes with a half-life of 10 to 15 minutes. This first phase corresponds clinically to the anesthetic effect of the drug. </paragraph>
                           </text>
                           <effectiveTime value="20220330"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_aaf887c1-ce47-4f75-a054-0f9dacc05ec6">
                           <id root="0d2af717-928a-4775-8976-fd38dca515e3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Elimination</content>
                              <br/>
                           </title>
                           <text/>
                           <effectiveTime value="20220330"/>
                           <component>
                              <section ID="LINK_65109b55-d581-4a34-8a12-d2a78f5c53fe">
                                 <id root="f6851681-d36b-4fca-89c8-d4f2753ad565"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>
                                    <content styleCode="italics">Metabolism</content>
                                 </title>
                                 <text>
                                    <paragraph>Ketamine is metabolized via N-dealkylation to the active metabolite norketamine primarily by CYP2B6 and CYP3A4 and to a lesser extent by other CYP enzymes. Norketamine undergoes hydroxylation of the cyclohexone ring to form hydroxynorketamine compounds via CYP-dependent pathways, which are conjugated with glucuronic acid and subsequently undergo dehydration of the hydroxylated metabolites to form the cyclohexene derivative dehydroxynorketamine. </paragraph>
                                 </text>
                                 <effectiveTime value="20220330"/>
                              </section>
                           </component>
                           <component>
                              <section ID="LINK_1fd65a0a-13c4-4474-9926-4e496fbb08f4">
                                 <id root="5432aa41-038a-49c3-82ff-e0822a4e1bb4"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title>
                                    <content styleCode="italics">Excretion </content>
                                 </title>
                                 <text>
                                    <paragraph>Following intravenous administration, the ketamine concentration decreases due to a combination of redistribution from the CNS to slower equilibrating peripheral tissues and hepatic biotransformation to norketamine. The redistribution half-life of ketamine from the CNS to slower equilibrating peripheral tissues (beta phase) is 2.5 hours.</paragraph>
                                 </text>
                                 <effectiveTime value="20220330"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_c2572e58-edad-4537-8d10-d7604ce8cfa5">
               <id root="2eb43843-9f5c-4bfd-809c-68c59db7f201"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20220330"/>
               <component>
                  <section ID="LINK_b5001311-08ec-4183-bf6c-60649bfdf367">
                     <id root="4857e988-940d-42a9-9f0c-8c61917dda7e"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text/>
                     <effectiveTime value="20220330"/>
                     <component>
                        <section ID="LINK_d4513656-fca5-41b2-b288-76a6643344d9">
                           <id root="c551e4c0-8634-4d6d-bf95-92400ef4f72a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Carcinogenesis</content>
                           </title>
                           <text>
                              <paragraph>Long-term animal studies have not been conducted to evaluate the carcinogenic potential of ketamine.</paragraph>
                           </text>
                           <effectiveTime value="20220330"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_a2e66663-645f-403c-ba4f-cce160fa2f7c">
                           <id root="2ed99dc5-9b7e-4198-a851-3c05b06ad75b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Mutagenesis</content>
                           </title>
                           <text>
                              <paragraph>In a published report, ketamine was clastogenic in the in vitro chromosomal aberration assay.</paragraph>
                           </text>
                           <effectiveTime value="20220330"/>
                        </section>
                     </component>
                     <component>
                        <section ID="LINK_a82ac133-076a-44ae-b9a4-34a38b7fdfd6">
                           <id root="0438d506-340f-4a1b-a36f-844c19fb8e25"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <title>
                              <content styleCode="underline">Impairment of
Fertility</content>
                           </title>
                           <text>
                              <paragraph>Adequate studies to evaluate the impact of ketamine on male or female fertility have not been conducted. Male and female rats were treated with 10 mg/kg ketamine IV (0.8 times the average human induction dose of 2 mg/kg IV based on body surface area) on Days 11, 10, and 9 prior to mating. No impact on fertility was noted; however, this study design does not adequately characterize the impact of a drug on fertility endpoints.</paragraph>
                           </text>
                           <effectiveTime value="20220330"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="LINK_de2d5267-3b62-4daf-86a7-621501868029">
                     <id root="91251e31-a9ef-419e-aa86-8769d8355c38"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <text>
                        <paragraph>Published studies in animals demonstrate that the use of anesthetic agents during the period of rapid brain growth or synaptogenesis results in widespread neuronal and oligodendrocyte cell loss in the developing brain and alterations in synaptic morphology and neurogenesis. Based on comparisons across species, the window of vulnerability to these changes is believed to correlate with exposures in the third trimester through the first several months of life, but may extend out to approximately 3 years of age in humans.</paragraph>
                        <paragraph>In primates, exposure to 3 hours of an anesthetic regimen that produced a light surgical plane of anesthesia did not increase neuronal cell loss, however, treatment regimens of 5 hours or longer increased neuronal cell loss. Data in rodents and in primates suggest that the neuronal and oligodendrocyte cell losses are associated with subtle but prolonged cognitive deficits in learning and memory. The clinical significance of these nonclinical findings is not known, and healthcare providers should balance the benefits of appropriate anesthesia in neonates and young children who require procedures against the potential risks suggested by the nonclinical data <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_df5cfdae-63db-4348-928a-864b45d3b013">5.5)</linkHtml>, Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_e475f237-3e80-443e-8922-4a4c39273af8">8.1</linkHtml>, <linkHtml href="#www.splportal.comLINK_916f38a7-8120-4f83-a121-cb8dc49742ff">8.4</linkHtml>)]</content>.</paragraph>
                        <paragraph>In published studies, intraperitoneal administration of ketamine at doses greater than 40 mg/kg induced vacuolation in neuronal cells of the posterior cingulate and retrosplenial cortices in adult rats, similar to what has been reported in rodents administered other NMDA receptor antagonists. These vacuoles were demonstrated to be reversible and did not progress to degeneration or neuronal death up to doses of 80 mg/kg (1.2 times the human dose of 10 mg/kg based on body surface area). A no-effect level for neuronal vacuolation was 20 mg/kg intraperitoneal (0.3 times a human dose of 10 mg/kg on a body surface area basis). The window of vulnerability to these changes is believed to correlate with exposures in humans from the onset of puberty through adulthood. The relevance of this finding to humans is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20220330"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_764d6076-c8f5-4477-bc21-22b4415393e1">
               <id root="c37550f0-3fa7-4da7-94e6-55a43569e74a"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>KETALAR has been studied in over 12,000 operative and diagnostic procedures, involving over 10,000 patients in 105 separate studies. During the course of these studies, KETALAR was administered as the sole general anesthetic, as an induction agent prior to administration of other general anesthetics, or to supplement other anesthetic agents. </paragraph>
                  <paragraph>KETALAR has been evaluated during the following procedures: </paragraph>
                  <list listType="ordered" styleCode="Arabic">
                     <item>debridement, dressing changes, and skin grafting in burn patients, as well as other superficial surgical procedures. </item>
                     <item>neurodiagnostic procedures such as myelograms and lumbar punctures. </item>
                     <item>diagnostic and operative procedures of the ear, nose, and mouth, including dental extractions. </item>
                     <item>sigmoidoscopy and minor surgery of the anus and rectum, and circumcision. </item>
                     <item>extraperitoneal procedures, such as dilatation and curettage. </item>
                     <item>orthopedic procedures such as closed reductions, manipulations, femoral pinning, amputations, and biopsies. </item>
                     <item>cardiac catheterization procedures. </item>
                  </list>
               </text>
               <effectiveTime value="20220330"/>
            </section>
         </component>
         <component>
            <section ID="LINK_41e52bc8-d10d-4ee3-975d-4a2953a2c10f">
               <id root="e3720ab1-df79-4ea3-9bc6-ad318d26bac4"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">How Supplied</content>
                  </paragraph>
                  <paragraph>KETALAR injection is a clear, colorless solution supplied as the hydrochloride salt in concentrations equivalent to ketamine base, as follows:</paragraph>
                  <table>
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Unit of sale</content>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> <content styleCode="bold">Strength </content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>NDC 42023-113-10</paragraph> Unit of 10</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>200 mg in 20 mL multiple- dose vial (10 mg/mL)</paragraph> 10 mg ketamine base (equivalent to 11.53 mg ketamine hydrochloride) </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>NDC 42023-114-10</paragraph> Unit of 10</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>500 mg in 10 mL multiple- dose vial (50 mg/mL)</paragraph> 50 mg ketamine base (equivalent to 57.67 mg ketamine hydrochloride)</td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>NDC 42023-115-10</paragraph> Unit of 10</td>
                           <td styleCode=" Botrule Toprule Lrule Rrule"> <paragraph>500 mg in 5 mL multiple- dose vial (100 mg/mL)</paragraph> 100 mg ketamine base (equivalent to 115.33 mg ketamine hydrochloride)</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="underline">Storage and Handling</content>
                  </paragraph>
                  <paragraph>KETALAR injection should be stored at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F)<content styleCode="italics"> [see USP Controlled Room Temperature]</content>. Protect from light.</paragraph>
               </text>
               <effectiveTime value="20220330"/>
            </section>
         </component>
         <component>
            <section ID="LINK_c622e28f-79e7-46a5-abd4-55065e670727">
               <id root="743f673d-71fd-4130-a61b-747d461fccfe"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>Studies conducted in young animals and children suggest repeated or prolonged use of general anesthetic or sedation drugs in children younger than 3 years may have negative effects on their developing brains. Discuss with parents and caregivers the benefits, risks, and timing and duration of surgery or procedures requiring anesthetic and sedation drugs <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_df5cfdae-63db-4348-928a-864b45d3b013">5.5</linkHtml>)]</content>.</item>
                  </list>
                  <list listType="unordered" styleCode="Disk">
                     <item>Due to the residual anesthetic effects and the potential for drowsiness, advise patients not to drive an automobile, operate hazardous machinery, or engage in hazardous activities within 24 hours of receiving KETALAR. </item>
                  </list>
               </text>
               <effectiveTime value="20220330"/>
            </section>
         </component>
         <component>
            <section ID="LINK_7ca79948-1803-490a-894b-d6fd6ed1adee">
               <id root="8a75e4a7-b00f-4b8b-add3-4c6b85305bd6"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title/>
               <text>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>Endo USA</paragraph>
                  <paragraph>Malvern, PA 19355</paragraph>
                  <paragraph>© 2024 Endo, Inc. or one of its affiliates.</paragraph>
                  <paragraph>R07/2024</paragraph>
               </text>
               <effectiveTime value="20220330"/>
            </section>
         </component>
         <component>
            <section ID="LINK_6a67e6d5-160d-4227-85b6-263b5f599ddd">
               <id root="9806f90d-5963-4f22-b291-62b4118c2c66"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <renderMultiMedia referencedObject="MM2"/>
               </text>
               <effectiveTime value="20220330"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>200mg/20mL Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ketalar-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_f1fa0c60-9065-4040-a22d-2dbedde5a86a">
               <id root="f7144247-dc41-4276-9410-783726dfb740"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20220330"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>500mg/10mL Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ketalar-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_e832893e-b702-4053-9aa9-d6cb3b9418bc">
               <id root="9057eebb-1824-4c56-bcc8-0429083b523c"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20220330"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>500mg/5mL Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="ketalar-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>